Clinical Trials Browser

Neoplasm Metastasis, Neoplasms

Neoplasm Metastasis

Adenocarcinoma, Neoplasms

Neoplasm Metastasis, Neoplasms

Carcinoma, Squamous Cell

Adenocarcinoma

Neoplasm Metastasis, Neoplasms

Carcinoma, Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis, Neoplasms

Neoplasm Metastasis

Neoplasm Metastasis, Neoplasms

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis, Neoplasms

Neoplasm Metastasis, Neoplasms

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis

Neoplasm Metastasis

Clinical Trials

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

A Study of ASP3082 in Adults With Advanced Solid Tumors

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

LUCERNA

Pan Tumor Rollover Study

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

KEYNOTE-E12

KEYNOTE-630

KEYLYNK-008

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

IMbrella B

CICILIA

A Study of YL242 in Subjects With Advanced Solid Tumors

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

PanTumor-101

FORTIFY

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

HAMMER

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

BOREALIS-1

Catalyst

EIK1001

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

MK-4464-001

MK-4830-001

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

AURORAS-1

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

MK-0482-001

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

MK-9999-01B

MK-6482-016

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

IO-001

ARTISTRY-3

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile